Data from a phase 1b study of quemliclustat-based regimens showed promising overall survival in treatment-naÏve metastatic pancreatic cancer

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus) today announced promising overall survival data from arc-8, a phase 1b study that is being co-developed with gilead sciences. arc-8 is the study of quemliclustat, an investigational small molecule cd73 inhibitor, plus chemotherapy with or without zimberelimab, an investigational anti-pd-1 antibody, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mpdac). the results will be presented during t.
RCUS Ratings Summary
RCUS Quant Ranking